Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290199 | 0.87 | HCRTR1 (0.41) | KDM4EMAPTSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4284003 | 0.87 | HCRTR1 (0.41) | KDM4EMAPTSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4287265 | 0.86 | KDM4E (0.45) | KDM4EMEN1KMT2AHTR1BALDH1A1 | |
| SCHEMBL4282070 | 0.85 | NPC1 (0.48) | KDM4EHCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL4290115 | 0.85 | ALDH1A1 (0.45) | KDM4EPOLBMAPTSMN1; SMN2HCRTR1 | |
| SCHEMBL4285580 | 0.85 | CPS1 (0.46) | KDM4EHCRTR1HCRTR2LMNA | |
| SCHEMBL4290602 | 0.83 | HCRTR1 (0.39) | KDM4EPOLBMAPTSMN1; SMN2HCRTR1 | |
| SCHEMBL4281735 | 0.83 | HCRTR1 (0.38) | KDM4EHCRTR1HCRTR2KDM1AL3MBTL1 | |
| SCHEMBL4284656 | 0.80 | FFAR1 (0.42) | KDM4EPOLBSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL4294041 | 0.80 | HCRTR1 (0.40) | KDM4EPOLBHCRTR1HCRTR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885POLB 3799/4885PKM 847/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885POLB 3799/4885PKM 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.